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Cardiometabolic Consequences
of Gestational Dysglycemia
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Toronto, Ontario, Canada
The development of gestational diabetes and even milder forms of dysglycemia during pregnancy represents a
maternal phenotype at increased subsequent risk for developing type 2 diabetes mellitus, metabolic syndrome,
and, with time, overt cardiovascular disease. A careful and systematic dissection of the hormonal, metabolic,
and vascular changes occurring in such women during pregnancy and over the postpartum years provides a
unique opportunity to identify conventional and novel conditions and biomarkers whose modification may atten-
uate adverse long-term outcomes, particularly cardiovascular risk. The purpose of this review is to summarize
current understanding of the magnitude of such risk and its potential causes, with a particular focus on postpar-
tum alterations in endothelial and vascular smooth muscle responsiveness. (J Am Coll Cardiol 2013;62:
677–84) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.080Gestational diabetes mellitus (GDM), defined as glucose
intolerance of varying severity with first onset or recognition
during pregnancy (1), represents a failure of the pancreas to
respond to the progressive insulin resistance of the latter
stages of gestation by appropriately increasing beta-cell mass
(2) and insulin secretion (3). Although in the majority of
patients, hyperglycemia resolves postpartum, in the years
after pregnancy, these women exhibit greater risk for devel-
oping type 2 diabetes mellitus (T2DM) (4,5) and overt
cardiovascular disease (CVD) (6,7). Thus, detection of
GDM affords clinicians opportunities to care longitudinally
for a relatively young population at increased risk for
cardiovascular events and to intervene early to modify such
risk. The purpose of this review is to summarize both
epidemiological data concerning the cardiometabolic con-
sequences of gestational dysglycemia and current under-
standing regarding altered vascular properties that increase
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cular events.
Gestational Dysglycemia: Diagnosis and Therapy
Over the past 5 decades, a number of diagnostic criteria for
GDM with different thresholds have been proposed (8–11).
These are still applied, with modifications (12), but the
absence of an agreed global diagnostic standard has hin-
dered large-scale evaluation of the prevalence of GDM (13).
The American Diabetes Association now advises universal
third-trimester screening (12). Earlier American Diabetes
Association guidelines incorporated an assessment of GDM
risk (Table 1) and recommended either a 1-step approach,
with a diagnostic 75-g or 100-g oral glucose tolerance test
(OGTT) alone, or a 2-step process with a screening 50-g
glucose challenge test (GCT) at first presentation and, if
positive, an OGTT (Table 2). Women can be classified into
4 distinct groups by their responses: normal GCT normal
glucose tolerance (NGT) (normal GCT result, normal
OGTT result), abnormal GCT NGT (elevated GCT result
but normal OGTT result), gestational impaired glucose
tolerance (GIGT) (1 elevated glucose value on OGTT),
and GDM (2 elevated glucose values on OGTT) (14)
(Table 2). It is now evident that these milder degrees of
glucose intolerance also place the mother (15) at increased
postpartum cardiovascular risk. GDM is managed initially
with diet and lifestyle modification and, if this fails, with
insulin therapy (16). Postpartum, glycemic status should be
reassessed by an OGTT at 6 to 12 weeks and then at regular
intervals thereafter.
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Estimates of Subsequent
Cardiovascular Risk
Carr et al. (7) used questionnaire
methodology to evaluate CVD risk
in women with family histories of
T2DM who were on average 29.9
years postpartum. The self-reported
prevalence of CVD (stroke and/or
coronary artery disease) was signifi-
cantly greater in those with (n 
332) than without (n 662) GDM
(adjusted odds ratio [OR]: 1.85;
95% confidence interval [CI]: 1.21
to 2.82; p  0.005). This relation-
ship was still significant after adjust-
ment for age, ethnicity, and meno-
pausal status (OR: 1.66; 95% CI:
1.07 to 2.57; p 0.02), suggesting a
role for GDM itself in the causality
of CVD. Of interest, in that study,
women with GDM who self-
reported coronary artery disease
were on average 7 years younger
than those who did not have GDM
(45.5  2.2 years vs. 52.5  1.9
years, p  0.02).
In a retrospective population-
based study, Retnakaran and
Shah (15) linked Ontario data-
ases comprising all live births from 1994 to 1998 with
rovincial reimbursements for OGTTs. Women were strat-
fied into 3 groups: 1) with GDM (n  13,888); 2) with
bnormal OGTT results but not GDM (presumed to have
ilder forms of gestational dysglycemia, e.g., GIGT and
levated GCT NGT; n  71,831); and 3) who did not
ndergo OGTTs. The latter (n  349,977) were presumed
o have normal GCT results and thus normoglycemia
uring pregnancy. These cohorts then were followed for a
edian of 12.3 years. Cardiovascular event rates (compris-
ng hospitalizations for myocardial infarction, revasculariza-
Abbreviations
and Acronyms
AUCgluc  area under the
glucose curve
BMI  body mass index
CI  confidence interval
CVD  cardiovascular
disease
EDD  endothelium-
dependent dilation
EID  endothelium-
independent dilation
FMD  flow-mediated
dilation
GCT  glucose challenge
test
GDM  gestational
diabetes mellitus
GIGT  gestational
impaired glucose tolerance
HR  hazard ratio
NGT  normal glucose
tolerance
NO  nitric oxide
OGTT  oral glucose
tolerance test
OR  odds ratio
T2DM  type 2 diabetes
mellitus
American Diabetic Association2003 to 2004 Guidelines to AssessPregnancy at Risk for Ges ational Diabetes (16,72)
Table 1
American Diabe ic Association
2003 to 2004 Guidelines to Assess
Pregnancy at Risk for Gestational Diabetes (16,72)
Low Risk High Risk
Age  25 yrs
Caucasian Native American, Hispanic American,
Asian American, African
American, Pacific Islander
Normal pre-pregnancy BMI Obesity
No first-degree relatives with T2DM T2DM in a first-degree relative
No history of a GDM pregnancy or T2DM History of GDM or glycosuria
No history of a complicated delivery
(e.g., macrosomia)(BMI  body mass index; GDM  gestational diabetes mellitus; T2DM  type 2 diabetes mellitus.ion by coronary artery bypass grafting or angioplasty,
troke, and carotid endarterectomy) per 10,000 person-years
f women with GDM, presumed milder dysglycemia, and
resumed normoglycemia were 4.2, 2.3, and 1.9, respectively
Fig. 1). After adjustment for confounding variables the hazard
atios (HRs) for CVD of women with GDM and presumed
ilder dysglycemia were 1.66 (95% CI: 1.3 to 2.13; p 0.001)
nd 1.19 (95% CI: 1.02 to 1.39; p  0.03), respectively.
owever, after adjustment for the development of T2DM,
Rs for CVD were no longer significant for GDM (HR: 1.25;
5% CI: 0.96 to 1.62; p  0.10) and for presumed milder
ysglycemia (HR: 1.16; 95% CI: 0.99 to 1.36; p  0.06).
ardiometabolic Consequences
f Gestational Dysglycemia
re-diabetes and T2DM. Both GDM and milder mani-
estations of gestational dysglycemia predispose to dysgly-
emia soon after delivery (4), and 20% to 30% of women
ith GDM will develop T2DM (17–19) within the first 5
ears postpartum (5), in part because of persistent pancreatic
eta-cell dysfunction (20–22). In 1 study, 400 women
ere evaluated 3 months postpartum for glucose intolerance
4) as defined by Canadian Diabetes Association clinical
ractice guidelines (Table 3) (23). The prevalence of com-
ined T2DM and prediabetes was 3.2% in the normal GCT
GT group, 10.2% in the abnormal GCT NGT group,
6.5% in the GIGT group, and 32.8% in the GDM group
ptrend 0.0001). Most of this dysglycemia was in fact
xplained by the differing prevalence of postpartum im-
aired glucose tolerance (i.e., 2.2% impaired glucose toler-
nce for normal GCT NGT vs. 27% impaired glucose
olerance for GDM). The independent predictors of diabe-
es and pre-diabetes at 3 months postpartum were GDM
Approaches to the Diagnosis of GDM:1-Step (12) and 2-Step Algorithms (14)Table 2 Approaches to the Diagnosis of GDM:1-Step (12) and 2-Step Algorithms (14)
Approach mmol/l mg/dl
75-g 1-step approach (IADPSG guidelines): requirement
1 abnormal value for GDM diagnosis
FPG 5.1 92
1-h plasma glucose 10.0 180
2-h plasma glucose 8.5 153
2-step approach (NDDG guidelines)
Step 1
50-g GCT
1-h plasma glucose 7.8 140
Step 2: requirement 2 abnormal values for
GDM diagnosis
100-g OGTT
FPG 5.8 105
1-h plasma glucose 10.6 190
2-h plasma glucose 9.2 165
3-h plasma glucose 8.1 145
FPG  fasting plasma glucose; GCT  glucose challenge test; GDM  gestational diabetes
mellitus; IADPSG  International Association of Diabetes and Pregnancy Study Group; NDDG 
National Diabetes Data Group; OGTT  oral glucose tolerance test.OR: 14.3; 95% CI: 4.2 to 49.1), GIGT (OR: 5.7; 95% CI:
G
w
t
g
w
a
679JACC Vol. 62, No. 8, 2013 Brewster et al.
August 20, 2013:677–84 Cardiometabolic Risk of Gestational Diabetes1.6 to 21.1), and abnormal GCT NGT (OR: 3.6; 95% CI:
1.01 to 12.9). An increased risk for dysglycemia was still
evident in women with GDM and GIGT at 12 months
postpartum and was accompanied by diminished pancreatic
beta-cell function (21). This chronic deficiency of pancreatic
beta-cell function in women with GDM (3) may in some
predate pregnancy (24).
Metabolic syndrome. Postpartum metabolic syndrome in
DM has been well described (25,26). When a cohort of
omen (n  487) were classified 3 months postpartum on
he basis of the 2005 International Diabetes Federation
uidelines (27), prevalence of the metabolic syndrome
as 10% in those with NGT, 17.6% in those with GIGT,
nd 20% in those with GDM (p  0.016) (28). In that
series, gestational dysglycemia was the only independent
Figure 1 CVD-Free Survival in Women With Gestational Normog
Kaplan-Meier survival curves for cardiovascular disease (CVD)–free survival in wom
went oral glucose tolerance tests (OGTTs) but did not have GDM (presumed milde
moglycemia in pregnancy) (green line). Reprinted, with permission, from Retnakar
Canadian Diabetes AssociationRecommended Criteria for Diagnosisof Type 2 and P e-Diabete (23)
Table 3
Canadi Diabetes Association
Recommended Criteria for Diagnosis
of Type 2 Diabetes and Pre-Diabetes (23)
Degree of Dysglycemia Fasting 2-h Glucose
Diabetes 7 mmol/l
(126 mg/dl)
11.1 mmol/l
(199 mg/dl)
Pre-diabetes
IFG 6.1–6.9 mmol/l
(110–125 mg/dl)
7.8 mmol/l
(140 mg/dl)
IGT 6.1 mmol/l
(110 mg/dl)
7.8–11.0 mmol/l
(140–199 mg/dl)
Combined IFG and IGT 6.1–6.9 mmol/l
(110–125 mg/dl)
7.8–11.0 mmol/l
(140–199 mg/dl)
Normoglycemia 6.1 mmol/l
(110 mg/dl)
7.8 mmol/l
(140 mg/dl)IFG  impaired fasting glucose; IGT  impaired glucose tolerance.predictor of postpartum metabolic syndrome. For women
with GIGT, the OR was 2.16 (95% CI: 1.05 to 4.42),
and for those with GDM, the OR was 2.05 (95% CI:
1.07 to 3.94).
Dyslipidemia. In a similar study population, Retnakaran
et al. (29) found that GDM was an independent predictor
of plasma total cholesterol, low-density lipoprotein, and
triglyceride concentrations at 3 months postpartum. In
addition, there were graded increases in total cholesterol
(p  0.0047), low-density lipoprotein (p  0.0002), and
triglyceride (p  0.0002) across the classes of gestational
dysglycemia, from normal GCT NGT to GDM.
Hypertension. An increased risk for postpartum hyperten-
sion in women with gestational dysglycemia also has been
reported. At 3 months postpartum women with GIGT
(median: 110 mm Hg; interquartile range: 103.5 to 115.5
mm Hg; n 91) and those with GDM (median: 111 mm Hg;
range: 105 to 119.5 mm Hg; n  137) had significantly
higher systolic blood pressures than control subjects (me-
dian: 108 mm Hg; interquartile range: 102 to 114 mm Hg;
n  259) (p  0.0158 for comparison across groups) (28).
In another study, a cohort including both obese and
nonobese women with GDM examined 1 year postpar-
tum had significantly higher diastolic (p 0.002) and mean
(p 0.004) blood pressures and heart rates but lower stroke
volumes and cardiac output than a group of control women
without GDM (30).
Other risk factors. A prior GDM pregnancy has also been
associated with elevated plasma C reactive protein, a marker
ia and Dysglycemia During the Follow-Up Period
h previous gestational diabetes mellitus (GDM) (black line), women who under-
ycemia) (brown line), and women who did not undergo OGTTs (presumed nor-
Shah (15).lycem
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are more likely to have higher body mass indexes (BMIs)
before pregnancy (4), greater intrapregnancy weight gain
(32), and a higher incidence postpartum of polycystic ovary
syndrome (33).
Pathophysiology
It is now appreciated that the cardiovascular risk subsequent
to a GDM pregnancy resembles that which accrues to the
general female population once T2DM develops (34).
Indeed, several groups have proposed that cardiometabolic
abnormalities detected postpartum might have antedated
the gestational dysglycemic pregnancy (24,28,35). As a
consequence, attention following a GDM pregnancy has
focused on pathophysiological processes now considered to
contribute importantly to the vascular injury of T2DM.
Endothelial function. The vascular endothelium is now
recognized as a paracrine organ responsible for the produc-
tion of vasoactive autocoids such as nitric oxide (NO) (36).
Dysfunction of the endothelium is recognized as an early
precursor of coronary atherosclerosis (37), which when
present is systemic (38), can be assessed in peripheral
arteries, and is a surrogate for the coronary vasculature (39).
As summarized in Table 4, the endothelial function of
omen with gestational dysglycemia has been assessed in
everal ways at a number of time points postpartum, but
ith inconsistent results.
Ex vivo, endothelial and vascular smooth muscle respon-
iveness to exogenous stimuli can be assessed by placing
rterial segments obtained by subcutaneous fat biopsy in
ire myographs. One study, involving 14 patients with
DM and 18 controls examined at caesarian section,
eported a reduction in the endothelium-mediated vasodi-
ator response to acetylcholine. This was no longer evident
fter the administration of the prostaglandin inhibitor
ndomethacin; the smooth muscle response to nitroprusside
as similar in the 2 cohorts (40). NO synthase inhibition
educed acetylcholine responsiveness similarly in both
roups of women. The investigators proposed that maternal
ascular endothelial dysfunction could increase the risk for
ardiovascular disorders in women with prior GDM (40).
In a substudy of the Hyperglycemia and Adverse Preg-
ancy Outcomes trial (41), Banerjee et al. (42) obtained
luteal fat arteries by biopsy 2 years postpartum and exposed
hese vessels in myographs to carbachol (to assess
ndothelium-dependent dilation [EDD]), sodium nitro-
russide (to assess smooth muscle responsiveness), and the
asoconstrictor norepinephrine. By the time of biopsy, 5
omen had developed postpartum dysglycemia. Maximal
DD of arteries obtained from women with GDM (43.3%)
nd from women with milder gestational dysglycemia
51.7%) was reduced significantly relative to normoglycemic
ontrols (72.7%) (p  0.01 and p  0.04, respectively).
MI at the time of biopsy and hypercholesterolemia provedo be the strongest determinants of EDD, with BMI gmerging as the only significant determinant of arterial
unction. The investigators concluded that potentially re-
ersible vascular pathology was evident very early in women
t risk for subsequent T2DM. Although data acquired using
his ex vivo approach are instructive, this method has
imited application to clinical or population studies.
Flow-mediated dilation (FMD) is a noninvasive, repro-
ucible technique that is used widely to assess EDD, which
epresents the net of several factors, including endogenous
O synthesis and its local bioavailability (43). This method
nvolves ultrasound and Doppler imaging of a peripheral
rtery before and then after a period of ischemia, with
elative quantification of its resulting dilation (43). Vascular
esponsiveness to exogenously administered NO is often
ssessed at the same sitting as an internal control and as an
stimate of endothelium-independent dilation (EID). An
ttenuated FMD response is associated with several con-
entional cardiovascular risk factors (44–46) as well as
stablished CVD (47) and currently is considered prognos-
ic of increased cardiovascular risk (46,48,49).
Thus far, 4 published cross-sectional studies, conducted
t times ranging from intrapartum to 5 years postpartum,
ave evaluated FMD in women with gestational dysglyce-
ia (50–53). Paradisi et al. (50) assessed, in the third
rimester of pregnancy, FMD in women with GDM and
ith milder degrees of gestational dysglycemia. FMD was
ignificantly lower in both gestational dysglycemic groups
ompared with controls (GDM: 4.1  0.9%; dysglycemia:
7.6 1.1%; controls: 10.9 1.1%; p 0.0001 and p 0.04,
respectively). Area under the glucose curve (AUCgluc)
during pregnancy and nonesterified fatty acids indepen-
dently influenced FMD (p  0.0001 for both). The
investigators attributed the relationship with AUCgluc to
the effects of hyperglycemia (and possibly secondary
insulin resistance) on the generation and bioavailability of
endothelium-derived NO.
FMD in dysglycemic women assessed 2 months postpar-
tum was also influenced by AUCgluc (51). These subjects
were grouped into those with GDM who had by this time
become normoglycemic (n  10), those with GDM who
remained hyperglycemic (with some glucose concentrations
in the prediabetes range; n  10), those normoglycemic
during pregnancy (n  10), and control women who had
never been pregnant (n  10). FMD was impaired in
women with GDM who became normoglycemic (4.1 
2.3%) and in those who remained hyperglycemic (4.4 
0.9%) compared with normoglycemic (10.8  1.3%) and
control (12%) subjects (p  0.05). However after control-
ling for postpartum AUCgluc, differences in FMD were no
onger significant, highlighting the importance of postpar-
um hyperglycemia in determining endothelial function at
his early stage after pregnancy.
The most widely cited report is by Anastasiou et al. (52),
hose subjects were studied at 3 to 7 months postpartum,
hen normoglycemia was restored in all. They compared 3
roups: 1) women with previous GDM (BMI 27 kg/m2;
Studies Examining Vascular Responsiveness in Gestational DysglycemiaTable 4 Studies Examining Vascular Responsiveness in Gestational Dysglycemia
First Author
(Ref. #)
Duration With Respect
to Pregnancy Population Methods Conclusions Confounding Variables
Paradisi et al. (50) Third trimester Controls (n  15)
Milder dysglycemia (n  10)
GDM (n  13)
Brachial FMD 1. FMD was reduced in women with GDM (p  0.0001) and milder
dysglycemia (p  0.04) vs. controls
2. FMD was lower in GDM vs. milder dysglycemia group (p  0.04)
AUCgluc accounted for 35% variance
of FMD (p  0.0001) and NEFA
for 5% variance (p  0.0001)
Savvidou et al.
(59)
Third trimester GDM (n  34)
Controls (n  34)
Radial artery applanation tonometry 1. Increased augmentation index in GDM pregnancies (p  0.001)
2. Increased carotid-radial PWV (p  0.03) in women with GDM
1. Maternal age, pulse, aortic Tr
(p  0.0001 for all) and
presence of GDM (p  0.003)
were independent predictors of
augmentation index
2. PWV was not significantly
increased in women with GDM
after exclusion of women with
pre-eclampsia
Dollberg et al. (73) At term GDM (n  8)
Controls (n  5)
Measurement of NOS activity by
arginine-to-citrulline conversion
assay of placental vessels
Significantly greater NOS activity in resistance vessels of control
pregnancies (p  0.01)
Knock et al. (40) At term Controls (n  18)
GDM (n  14)
Wire myography of subcutaneous
fat biopsies
EDD was decreased in women with GDM vs. controls (p  0.01)
Davenport et al.
(51)
2 months Never pregnant controls (n  10)
NORM (n  10)
GDM-N (n  10)
GDM-H (n  10)
1. PWV
2. Brachial and carotid distensibility
3. Brachial FMD
1. FMD was significantly decreased in GDM-N and GDM-H vs. NORM
groups (p  0.01)
2. GDM-N and GDM-H groups had decreased brachial and carotid
distensibility vs. NORM and control groups (p  0.05)
3. No significant difference in PWV
1. Difference in FMD nonsignificant
after controlling for AUCgluc
2. Difference in brachial and carotid
distensibility nonsignificant after
controlling for insulin sensitivity,
AUCgluc, and TG
Anastasiou et al.
(52)
3–7 months Controls (n  19)
Nonobese GDM (n  17)
Obese GDM (n  16)
Brachial FMD 1. FMD was significantly decreased in women with GDM vs. controls (p 0.001)
2. EID was significantly reduced in obese women with GDM (p 0.05)
BMI was the main determinant of
EID (p  0.05)
Pleiner et al. (56) 4 months Obese women with previous
GDM (n  7) vs. nonobese
women with previous GDM
(n  5)
1. Venous plethysmography (FBF)
after ACh infusion
2. ADMA concentration
1. Reduced FBF to ACh in the overweight GDM group (p  0.05)
2. ADMA levels were positively correlated with BMI (p  0.05)
Banerjee et al.
(42)
2 yrs Controls (n  8)
UQ (n  13)
GDM (n  8)
Wire myography of subcut arteries
from gluteal fat biopsy
Significantly reduced EDD in both GDM (p  0.01) and UQ (p  0.04) vs.
controls
1. EDD correlated inversely with
BMI and hypercholesterolemia
on multiple regression
2. BMI was the most powerful
determinant of small artery
function
Hu et al. (60) 2–4 yrs Controls (n  20)
GDM (n  17)
1. Aortic and carotid artery stiffness
2. ACh iontophoresis
1. Increased carotid artery stiffness in women with previous GDM
pregnancies: Ep (p  0.006);  (p  0.05)
2. Peak perfusion increase in hand and foot skin lower in previous GDM
(both p  0.01 and p  0.04, respectively); women with GDM had
lower increases in perfusion over time in both hands and feet vs.
controls (p  0.001)
Multiple regression of stiffness
index found age to be the major
determinant (p  0.008)
Hannemann et al.
(53)
5 yrs Controls (n  17)
GDM (n  17)
1. Laser Doppler fluximetry of skin
MMVC to local heating
2. Brachial artery FMD
1. Impaired MMVC in women with previous GDM (p  0.008)
2. No difference in EDD or EID in women with GDM vs. controls
ACh acetylcholine; ADMA NG-dimethyl-L-arginine; aortic Tr time between start of systolic curve and inflection point; AUCgluc area under the glucose curve;  stiffness index; BMI bodymass index; EDD endothelium-dependent dilation; EID endothelium-independent dilation; Ep
pressure strain elasticmodulus; FBF forearm blood flow; FMD flow-mediated dilation; GDM gestational diabetesmellitus; GDM-H prior gestational diabetesmellitus, hyperglycemic postpartum; GDM-N prior gestational diabetesmellitus, normoglycemic postpartum;MMVCmaximum
microvascular vasodilatory capacity; NEFA nonesterified fatty acids; NORM normoglycemic pregnancy, normoglycemic postpartum; NOS nitric oxide synthase; PWV pulse-wave velocity; TG triglyceride; UQmilder forms of gestational dysglycemia.
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and 3) women who were nonobese and normoglycemic
during pregnancy (n  19). FMD was significantly lower in
the obese and nonobese GDM groups compared with
controls (mean  SE: 1.6  2.5%, 1.6  3.7%, and 10.3 
4.4%, respectively; p  0.001). Because EID was also
significantly reduced in the obese GDM women relative to
the controls (p  0.05), attenuated arterial dilation in this
group was likely due to both endothelial and smooth muscle
dysfunction. On multifactorial analysis, the only variable
contributing to this reduction in EID was BMI. On
univariate analysis, FMD was correlated with uric acid level,
BMI, total cholesterol, and insulin resistance, but multiple
regression analysis to determine the independent contribu-
tion of each variable was not performed. In a subgroup of
these women with GDM, FMD improved significantly
after ascorbic acid was administered (54). This finding, as
well as the identification of increased plasma urate, led the
investigators to propose that the generation of oxygen-
derived free radicals impaired endothelial responsiveness in
this particular cohort.
In contrast, however, in a small study of normoglycemic
women examined 5 years postpartum, no between-group
differences in FMD were detected (GDM: 1.65% [range:
0.5% to 9.07%]; controls: 2.77% [range: 0.63% to 6.6%];
p  0.42) (53), suggesting that any abnormalities of EDD
detected early postpartum are reversible and not indicative
of a substrate for increased vascular risk from GDM.
However, because those with prior GDM had laser Doppler
evidence of microvascular dysfunction, the investigators
proposed that NO bioavailability remains impaired, result-
ing in altered microcirculatory vasoreactivity (53). Addi-
tional support for this latter concept is provided by obser-
vations that GDM pregnancies (55) and vascular
dysfunction in women with previous GDM are both ac-
companied by increased plasma concentrations of the en-
dogenous NO synthase inhibitor NG-dimethyl-L-arginine
(56). Dyslipidemia may also blunt endothelium-mediated
dilation in this population (57), and low-density lipoprotein
reduction secondary to orlistat therapy has been found to
improve the forearm blood flow dilatory response to intrabra-
chial infusion of acetylcholine (58).
Thus, as yet, there is no definitive evidence that FMD is
impaired late postpartum or that its assessment late post-
partum is a useful means of identifying women at highest
risk for future cardiovascular events. Moreover, interpreta-
tion of the currently available research is limited by the small
number of subjects studied to date and incomplete adjust-
ment for comorbidities or potential confounding factors
known to independently influence FMD. Consequently,
this area merits more comprehensive future research.
Smooth muscle function. Reports of attenuated EID in
women with prior GDM (42,52), often in association with
obesity, coupled with documentation of decreased arterial
distensibility (51) and increased arterial stiffness (59,60)provide evidence for altered smooth muscle, in addition to
altered endothelial, function.
Markers of inflammation. Subclinical inflammation, me-
diated in part through the paracrine action of adipocytes
(61), appears present in both GDM (30) and T2DM (62)
and predictive of increased cardiovascular events in the
female population (63). Adiponectin expression is reduced
in obesity, insulin resistance, and T2DM (64–67) and when
measured early in pregnancy, low adiponectin concentra-
tions are associated with increased risk for developing a
GDM pregnancy (68,69). A recent study comparing mark-
ers of inflammation in women with prior GDM (30) found
significantly higher C-reactive protein, interleukin-6, and
plasminogen activator 1 and lower adiponectin concentra-
tions than in control subjects, but after adjustment for
confounders, only high C-reactive protein and low adi-
ponectin were associated with GDM. Microalbuminuria, a
signal of impaired endothelial function in T2DM (70), has
been reported also in women whose pregnancies were
complicated by GDM (71).
Conclusions
Gestational dysglycemia (GDM and milder forms of ges-
tational glucose intolerance) identifies a group of women
who are at increased risk not only for T2DM but also for an
earlier age of onset of CVD. The usefulness of identifying a
dysglycemic pregnancy is that it will identify a population of
women at increased subsequent cardiometabolic risk. Fur-
thermore, much of that risk, expressed as dysglycemia,
metabolic syndrome, and altered vascular physiology, be-
comes evident in the first few months postpartum. Detec-
tion of these conventional abnormalities affords clinicians an
opportunity to attenuate such risk by targeted intervention.
One goal of future investigation is to identify and validate as
potential useful postpartum screening tools and biomarkers
of subsequent vascular risk, including altered endothelial
responsiveness, that may be evident before diabetes, meta-
bolic syndrome, or cardiovascular events emerge.
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